Related Experiment Video
Updated: Aug 10, 2025
11:46
Extremely Rapid and Specific Metabolic Labelling of RNA In Vivo with 4-Thiouracil Ers4tU
Published on: August 22, 2019
11.0K
4-Methylumbelliferone Targets Revealed by Public Data Analysis and Liver Transcriptome Sequencing
Alexandra A Tsitrina1,2, Noreen Halimani3, Irina N Andreichenko3
1Koltzov Institute of Developmental Biology, 26 Vavilov Str., 119334 Moscow, Russia.
International Journal of Molecular Sciences
|February 11, 2023
Summary
4-methylumbelliferone (4MU) is a drug that inhibits hyaluronic acid synthesis. This study reveals 4MU targets multiple enzymes and transcription factors, including nuclear receptors, impacting cell metabolism.
Area of Science:
- Biochemistry
- Pharmacology
- Genomics
Background:
- 4-methylumbelliferone (4MU) is an approved drug for cholestasis.
- 4MU exhibits anti-inflammatory, anti-fibrotic, and anti-tumor properties in animal models.
- Its broad efficacy suggests diverse and unelucidated molecular targets.
Purpose of the Study:
- To identify the molecular targets of 4-methylumbelliferone (4MU).
- To elucidate the mechanisms underlying 4MU's diverse pharmacological effects.
- To investigate 4MU's impact on cellular metabolism and gene expression.
Main Methods:
- Analysis of public databases: PubChem BioAssay, GO pathways, and Protein Atlas.
- Comparative liver transcriptome analysis in mice treated with 4MU.
- Identification of potential enzyme and transcription factor targets.
Main Results:
- Public database analysis identified enzymes and transcription factors, including 13 nuclear receptors, as potential 4MU targets.
- Transcriptome analysis revealed modulation of genes involved in bile acid metabolism, gluconeogenesis, and immune response.
- 4MU administration reduced hepatic glycogen granule accumulation.
Conclusions:
- 4-methylumbelliferone (4MU) possesses multiple molecular targets.
- 4MU regulates cellular metabolism, potentially through modulating signaling pathways involving nuclear receptors.
- These findings provide insights into 4MU's therapeutic potential beyond cholestasis.
